Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Breast Cancer Poziotinib for HER2(+) Metastatic Breast Cancer Spectrum Pharmaceuticals, Inc.
Follicular Lymphoma Idelalisib for Treatment of Follicular Lymphoma Gilead Sciences
Solid Tumors STARTRK-2 Ignyta, Inc.
Prostate Cancer Prostate Cancer: TRUMPET Astellas Scientific & Medical Affairs, Inc.
Observational Miraca Registry of Hematopoietic Diseases Miraca Life Science
Observational CARIS Molecular Intelligence Registry Caris Life Sciences, Inc.
Non-Small Cell Lung Cancer Inivata Liquid Biopsy Inivata, Ltd.
Non-Small Cell Lung Cancer TR(ACE) Assay Clinical Specimen Study Biological Dynamics
Colorectal Cancer 2nd Line Colorectal Cancer Boston Biomedical, Inc
Pancreatic Cancer Artist 1 Pancreatic Cancer ARMO Biosciences
Multiple Myeloma Multiple Myeloma Melflufen Oncopeptides AB
Breast Cancer HER2(+) Breast Cancer Previously Treated with TDM-1 Daiichi Sankyo, Inc.
Small Cell Lung Cancer Trilaciclib for Previously-Treated Small Cell Lung Cancer G1 Therapeutics, Inc.
Non-Small Cell Lung Cancer Xcovery Xalt3 XCovery
Breast Cancer Tesetaxel for HER2(-) Metastatic Breast Cancer Odonate Therapeutics, LLC
Ovarian, Fallopian, or Peritoneal Cancer Niraparib plus Bevacizumab as First Line Maintenance TESARO, Inc.
Pancreatic Cancer First Line Treatment with Napabucasin plus Nab-Paclitaxel and Gemcitabine Boston Biomedical, Inc.
Non-Small Cell Lung Cancer Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Small Cell Lung Cancer Second Line Irinotecan Versus Topotecan IPSEN Bioscience, Inc.
Acute Myeloid Leukemia Second Line Therapy for IDH1 Mutated Acute Myeloid Leukemia FORMA Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma Avelumab for Patients Previously Treated with Rituximab-Based Chemotherapy Pfizer
Urothelial Cancer Second Line Durvalumab plus Tremelimumab AstraZeneca
Hereditary Hemochromatosis Human Hepcidin for Patients Prescribed Therapeutic Phlebotomy La Jolla Pharmaceutical Company
Essential Thrombocythemia Ruxolitinib Versus Anagrelide in Patients Resistant or Intolerant to Hydroxyurea Incyte Corporation